This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1998 Jun;17(2):195-202.

doi: 10.1023/a:1006054421970.

The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A

D Yu¹, M C Hung

Affiliations

PMID: 9770116
DOI: 10.1023/a:1006054421970

Review

The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A

D Yu et al. Cancer Metastasis Rev. 1998 Jun.

. 1998 Jun;17(2):195-202.

doi: 10.1023/a:1006054421970.

Authors

D Yu¹, M C Hung

Affiliation

¹ Department of Tumor Biology, University of Texas, M.D. Anderson Cancer Center, Houston, USA.

PMID: 9770116
DOI: 10.1023/a:1006054421970

No abstract available

PubMed Disclaimer

Similar articles

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.
Hung MC, Hortobagyi GN, Ueno NT. Hung MC, et al. Adv Exp Med Biol. 2000;465:171-80. doi: 10.1007/0-306-46817-4_16. Adv Exp Med Biol. 2000. PMID: 10810625 Review. No abstract available.
A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.
Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.
Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo.
Zang RY, Shi DR, Lu HJ, Cai SM, Lu DR, Zhang YJ, Qin HL. Zang RY, et al. Int J Gynecol Cancer. 2001 Jan-Feb;11(1):18-23. doi: 10.1046/j.1525-1438.2001.011001018.x. Int J Gynecol Cancer. 2001. PMID: 11285029
Gene therapy for HER-2-related cancer.
Holzmann D. Holzmann D. Mol Med Today. 1996 Apr;2(4):138-9. doi: 10.1016/1357-4310(96)88779-x. Mol Med Today. 1996. PMID: 8796873 No abstract available.
Therapeutic transfer of DNA encoding adenoviral E1A.
Deissler H, Opalka B. Deissler H, et al. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):1-10. doi: 10.2174/157489207779561471. Recent Pat Anticancer Drug Discov. 2007. PMID: 18221050 Review.

See all similar articles

Cited by

A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Su CM, Chang TY, Hsu HP, Lai HH, Li JN, Lyu YJ, Kuo KT, Huang MT, Su JL, Chen PS. Su CM, et al. Oncotarget. 2016 Sep 27;7(39):63924-63936. doi: 10.18632/oncotarget.11737. Oncotarget. 2016. PMID: 27590506 Free PMC article.
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC. Xie X, et al. Mol Cancer Ther. 2009 Aug;8(8):2375-82. doi: 10.1158/1535-7163.MCT-09-0056. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671744 Free PMC article.
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.
Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC Jr, Hortobagyi GN, Hung MC. Su JL, et al. Cancer Res. 2011 Nov 1;71(21):6878-87. doi: 10.1158/0008-5472.CAN-11-0295. Epub 2011 Sep 12. Cancer Res. 2011. PMID: 21911455 Free PMC article.
p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing.
Flinterman MB, Mymryk JS, Klanrit P, Yousef AF, Lowe SW, Caldas C, Gäken J, Farzaneh F, Tavassoli M. Flinterman MB, et al. Oncogene. 2007 Oct 18;26(48):6863-74. doi: 10.1038/sj.onc.1210497. Epub 2007 May 7. Oncogene. 2007. PMID: 17486071 Free PMC article.
A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin.
Ge Y, Zhang W, Qin J, Zhang C, Tian W, Zhang Q, Shao J, Li S, Fang L, Zheng J. Ge Y, et al. Med Oncol. 2019 Oct 28;36(12):96. doi: 10.1007/s12032-019-1325-6. Med Oncol. 2019. PMID: 31659495

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal